News & Updates
Filter by Specialty:
Pembrolizumab effective in R/M cutaneous squamous cell carcinoma
13 Aug 2020
byChristina Lau
Pembrolizumab has demonstrated efficacy and acceptable safety in patients with recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC) in the single-arm phase II KEYNOTE-629 trial, leading to US FDA approval for its use in patients with R/M cSCC not curable by surgery or radiation therapy.